Champions Oncology, Inc. (CSBR) P/E Ratio History
Historical price-to-earnings valuation from 2008 to 2026
Loading P/E history...
CSBR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Champions Oncology, Inc. (CSBR) trades at a price-to-earnings ratio of 18.2x, with a stock price of $6.02 and trailing twelve-month earnings per share of $-0.16.
The current P/E is 95% below its 5-year average of 361.4x. Over the past five years, CSBR's P/E has ranged from a low of 22.0x to a high of 1577.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, CSBR trades at a 18% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, CSBR trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CSBR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CSBR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $234M | 4.7Lowest | 4.67 | +49%Best | |
| $44B | 42.8 | 3.00 | +23% | |
| $30B | 22.8 | 0.56Best | +5% | |
| $12B | 27.7 | 0.87 | +21% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CSBR Historical P/E Data (2008–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | Fri Oct 31 2025 00:00:00 GM | $6.84 | $0.17 | 41.0x | -89% |
| FY2026 Q1 | $6.32 | $0.20 | 31.6x | -91% | |
| FY2025 Q4 | Wed Apr 30 2025 00:00:00 GM | $7.15 | $0.33 | 22.0x | -94% |
| FY2025 Q3 | Fri Jan 31 2025 00:00:00 GM | $10.99 | $0.45 | 24.6x | -93% |
| FY2023 Q2 | Mon Oct 31 2022 00:00:00 GM | $6.94 | $0.00 | 1577.3x | +336% |
| FY2023 Q1 | Sun Jul 31 2022 00:00:00 GM | $8.66 | $0.02 | 352.0x | -3% |
| FY2022 Q4 | Sat Apr 30 2022 00:00:00 GM | $7.68 | $0.04 | 216.9x | -40% |
| FY2022 Q3 | Mon Jan 31 2022 00:00:00 GM | $8.02 | $0.03 | 320.8x | -11% |
| FY2022 Q2 | Sun Oct 31 2021 00:00:00 GM | $9.77 | $0.04 | 268.4x | -26% |
| FY2022 Q1 | Sat Jul 31 2021 00:00:00 GM | $10.45 | $0.02 | 597.1x | +65% |
| FY2021 Q4 | Fri Apr 30 2021 00:00:00 GM | $10.73 | $0.04 | 301.4x | -17% |
| FY2019 Q4 | $9.08 | $0.01 | 687.9x | +90% |
Average P/E for displayed period: 361.4x
See CSBR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CSBR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CSBR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCSBR — Frequently Asked Questions
Quick answers to the most common questions about buying CSBR stock.
Is CSBR stock overvalued or undervalued?
CSBR trades at 18.2x P/E, below its 5-year average of 361.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CSBR's valuation compare to peers?
Champions Oncology, Inc. P/E of 18.2x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is CSBR's PEG ratio?
CSBR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2008-2026.